Aplaviroc
Aplaviroc
Aplaviroc (pronounced: ap-la-vi-roc) is a pharmaceutical drug that was developed for the treatment of HIV and AIDS. It belongs to the class of drugs known as CCR5 receptor antagonists.
Etymology
The name "Aplaviroc" is derived from a combination of syllables that do not have a specific meaning in English. It is a common practice in the pharmaceutical industry to create unique and distinctive names for new drugs.
Mechanism of Action
Aplaviroc works by blocking the CCR5 receptor on the surface of the CD4 cells. This prevents the HIV virus from entering the cells and multiplying, thereby slowing down the progression of the disease.
Development and Approval
Aplaviroc was developed by GlaxoSmithKline, a British multinational pharmaceutical company. However, the drug was discontinued in the late-stage clinical trials due to concerns about its safety profile.
Related Terms
- CCR5 receptor antagonist: A class of drugs that block the CCR5 receptor on the surface of the CD4 cells, preventing the HIV virus from entering the cells.
- CD4: A type of white blood cell that plays a crucial role in the immune system. It is the primary target of the HIV virus.
- HIV: Human Immunodeficiency Virus, a virus that attacks the immune system and causes AIDS.
- AIDS: Acquired Immunodeficiency Syndrome, a chronic, potentially life-threatening condition caused by the HIV virus.
- GlaxoSmithKline: A British multinational pharmaceutical company that developed Aplaviroc.
External links
- Medical encyclopedia article on Aplaviroc
- Wikipedia's article - Aplaviroc
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski